{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:43:53Z","timestamp":1785527033375,"version":"3.56.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41375-026-03014-0","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:10:25Z","timestamp":1782465025000},"page":"1721-1734","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Small interfering RNA-mediated silencing of mutant NPM1 suppresses acute myeloid leukemia via reversing KAT7 and p300-mediated histone acetylation"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6702-2840","authenticated-orcid":false,"given":"Yongqiang","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhi","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6018-0694","authenticated-orcid":false,"given":"Dongxue","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhien","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangjian","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixian","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4894-0953","authenticated-orcid":false,"given":"Jun","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5613-1195","authenticated-orcid":false,"given":"Jiong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanfen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"3014_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352.","journal-title":"N Engl J Med"},{"key":"3014_CR2","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","volume":"361","author":"ER Mardis","year":"2009","unstructured":"Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361:1058\u201366.","journal-title":"N Engl J Med"},{"key":"3014_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","volume":"150","author":"JS Welch","year":"2012","unstructured":"Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150:264\u201378.","journal-title":"Cell"},{"key":"3014_CR4","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481:506\u201310.","journal-title":"Nature"},{"key":"3014_CR5","doi-asserted-by":"crossref","unstructured":"Farina M, Malagola M, Bernardi S, Re F, Russo D, Avenoso D. Intensive chemotherapy versus venetoclax-based regimens in elderly patients with acute myeloid leukemia: is the chemotherapy era ending? J Clin Med. 2025;14.","DOI":"10.3390\/jcm14082759"},{"key":"3014_CR6","doi-asserted-by":"crossref","unstructured":"Arai H, Matsui H, Chi S, Utsu Y, Masuda S, Aotsuka N, et al. Germline variants and characteristic features of hereditary hematological malignancy syndrome. Int J Mol Sci. 2024;25.","DOI":"10.3390\/ijms25010652"},{"key":"3014_CR7","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","volume":"129","author":"M Levis","year":"2017","unstructured":"Levis M. Midostaurin approved for FLT3-mutated AML. Blood. 2017;129:3403\u20136.","journal-title":"Blood"},{"key":"3014_CR8","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1182\/bloodadvances.2019000174","volume":"4","author":"M Levis","year":"2020","unstructured":"Levis M, Perl AE. Gilteritinib: potent targeting of FLT3 mutations in AML. Blood Adv. 2020;4:1178\u201391.","journal-title":"Blood Adv"},{"key":"3014_CR9","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1182\/blood.2024024009","volume":"145","author":"AH Wei","year":"2025","unstructured":"Wei AH, Loo S, Daver N. How I treat patients with AML using azacitidine and venetoclax. Blood. 2025;145:1237\u201350.","journal-title":"Blood"},{"key":"3014_CR10","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615:920\u20134.","journal-title":"Nature"},{"key":"3014_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2025;43:75\u201384.","journal-title":"J Clin Oncol"},{"key":"3014_CR12","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1200\/JCO-25-01694","volume":"43","author":"ES Wang","year":"2025","unstructured":"Wang ES, Montesinos P, Foran J, Erba H, Rodr\u00edguez-Arbol\u00ed E, Fedorov K, et al. Ziftomenib in relapsed or refractory NPM1-mutated AML. J Clin Oncol. 2025;43:3381\u201390.","journal-title":"J Clin Oncol"},{"key":"3014_CR13","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1038\/s41375-022-01666-2","volume":"36","author":"R Ranieri","year":"2022","unstructured":"Ranieri R, Pianigiani G, Sciabolacci S, Perriello VM, Marra A, Cardinali V, et al. Current status and future perspectives in targeted therapy of NPM1-mutated AML. Leukemia. 2022;36:2351\u201367.","journal-title":"Leukemia"},{"key":"3014_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1182\/blood.2020008211","volume":"137","author":"B Falini","year":"2021","unstructured":"Falini B, Brunetti L, Martelli MP. How I diagnose and treat NPM1-mutated AML. Blood. 2021;137:589\u201399.","journal-title":"Blood"},{"key":"3014_CR15","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-13-3270","volume":"20","author":"DB Johnson","year":"2014","unstructured":"Johnson DB, Smalley KS, Sosman JA. Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Clin Cancer Res. 2014;20:4186\u201392.","journal-title":"Clin Cancer Res"},{"key":"3014_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.beha.2019.05.004","volume":"32","author":"AM Hunter","year":"2019","unstructured":"Hunter AM, Sallman DA. Current status and new treatment approaches in TP53 mutated AML. Best Pr Res Clin Haematol. 2019;32:134\u201344.","journal-title":"Best Pr Res Clin Haematol"},{"key":"3014_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrc1885","volume":"6","author":"S Grisendi","year":"2006","unstructured":"Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer. 2006;6:493\u2013505.","journal-title":"Nat Rev Cancer"},{"key":"3014_CR18","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41375-024-02476-4","volume":"39","author":"B Falini","year":"2025","unstructured":"Falini B, Sorcini D, Perriello VM, Sportoletti P. Functions of the native NPM1 protein and its leukemic mutant. Leukemia. 2025;39:276\u201390.","journal-title":"Leukemia"},{"key":"3014_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1139\/bcb-2016-0068","volume":"94","author":"DD Scott","year":"2016","unstructured":"Scott DD, Oeffinger M. Nucleolin and nucleophosmin: nucleolar proteins with multiple functions in DNA repair. Biochem Cell Biol. 2016;94:419\u201332.","journal-title":"Biochem Cell Biol"},{"key":"3014_CR20","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"3014_CR21","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1182\/blood.2019004226","volume":"136","author":"B Falini","year":"2020","unstructured":"Falini B, Brunetti L, Sportoletti P, Martelli MP. NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood. 2020;136:1707\u201321.","journal-title":"Blood"},{"key":"3014_CR22","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMoa041974","volume":"352","author":"B Falini","year":"2005","unstructured":"Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254\u201366.","journal-title":"N Engl J Med"},{"key":"3014_CR23","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/leu.2009.124","volume":"23","author":"B Falini","year":"2009","unstructured":"Falini B, Bolli N, Liso A, Martelli MP, Mannucci R, Pileri S, et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia. 2009;23:1731\u201343.","journal-title":"Leukemia"},{"key":"3014_CR24","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/s41375-019-0681-8","volume":"34","author":"AJ Wang","year":"2020","unstructured":"Wang AJ, Han Y, Jia N, Chen P, Minden MD. NPM1c impedes CTCF functions through cytoplasmic mislocalization in acute myeloid leukemia. Leukemia. 2020;34:1278\u201390.","journal-title":"Leukemia"},{"key":"3014_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1083\/jcb.200711040","volume":"182","author":"P Bonetti","year":"2008","unstructured":"Bonetti P, Davoli T, Sironi C, Amati B, Pelicci PG, Colombo E. Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma. J Cell Biol. 2008;182:19\u201326.","journal-title":"J Cell Biol"},{"key":"3014_CR26","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/ncb1764","volume":"10","author":"M Wanzel","year":"2008","unstructured":"Wanzel M, Russ AC, Kleine-Kohlbrecher D, Colombo E, Pelicci PG, Eilers M. A ribosomal protein L23-nucleophosmin circuit coordinates Mizl function with cell growth. Nat Cell Biol. 2008;10:1051\u201361.","journal-title":"Nat Cell Biol"},{"key":"3014_CR27","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1172\/JCI97117","volume":"128","author":"X Gu","year":"2018","unstructured":"Gu X, Ebrahem Q, Mahfouz RZ, Hasipek M, Enane F, Radivoyevitch T, et al. Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest. 2018;128:4260\u201379.","journal-title":"J Clin Invest"},{"key":"3014_CR28","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jmb.2008.02.055","volume":"378","author":"M Gurumurthy","year":"2008","unstructured":"Gurumurthy M, Tan CH, Ng R, Zeiger L, Lau J, Lee J, et al. Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcription. J Mol Biol. 2008;378:302\u201317.","journal-title":"J Mol Biol"},{"key":"3014_CR29","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/leu.2008.326","volume":"23","author":"N Bolli","year":"2009","unstructured":"Bolli N, De Marco MF, Martelli MP, Bigerna B, Pucciarini A, Rossi R, et al. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. Leukemia. 2009;23:501\u20139.","journal-title":"Leukemia"},{"key":"3014_CR30","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1535-6108(04)00110-2","volume":"5","author":"S Kurki","year":"2004","unstructured":"Kurki S, Peltonen K, Latonen L, Kiviharju TM, Ojala PM, Meek D, et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell. 2004;5:465\u201375.","journal-title":"Cancer Cell"},{"key":"3014_CR31","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41375-020-0856-3","volume":"35","author":"R Ghasemi","year":"2021","unstructured":"Ghasemi R, Struthers H, Wilson ER, Spencer DH. Contribution of CTCF binding to transcriptional activity at the HOXA locus in NPM1-mutant AML cells. Leukemia. 2021;35:404\u201316.","journal-title":"Leukemia"},{"key":"3014_CR32","doi-asserted-by":"crossref","unstructured":"Oka M, Mura S, Otani M, Miyamoto Y, Nogami J, Maehara K, et al. Chromatin-bound CRM1 recruits SET-Nup214 and NPM1c onto HOX clusters causing aberrant HOX expression in leukemia cells. Elife. 2019;8:e46667.","DOI":"10.7554\/eLife.46667"},{"key":"3014_CR33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","volume":"34","author":"L Brunetti","year":"2018","unstructured":"Brunetti L, Gundry MC, Sorcini D, Guzman AG, Huang YH, Ramabadran R, et al. Mutant NPM1 maintains the leukemic state through HOX expression. Cancer Cell. 2018;34:499\u2013512.e499.","journal-title":"Cancer Cell"},{"key":"3014_CR34","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","volume":"13","author":"HJ Uckelmann","year":"2023","unstructured":"Uckelmann HJ, Haarer EL, Takeda R, Wong EM, Hatton C, Marinaccio C, et al. Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia. Cancer Discov. 2023;13:746\u201365.","journal-title":"Cancer Discov"},{"key":"3014_CR35","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1158\/2159-8290.CD-22-0424","volume":"13","author":"XQD Wang","year":"2023","unstructured":"Wang XQD, Fan D, Han Q, Liu Y, Miao H, Wang X, et al. Mutant NPM1 hijacks transcriptional hubs to maintain pathogenic gene programs in acute myeloid leukemia. Cancer Discov. 2023;13:724\u201345.","journal-title":"Cancer Discov"},{"key":"3014_CR36","doi-asserted-by":"publisher","first-page":"7118","DOI":"10.1016\/j.cell.2025.10.010","volume":"188","author":"GK Datar","year":"2025","unstructured":"Datar GK, Khabusheva E, Anand A, Beale J, Sadek M, Chen CW, et al. Disparate leukemia mutations converge on nuclear phase-separated condensates. Cell. 2025;188:7118\u2013.e7121.","journal-title":"Cell"},{"key":"3014_CR37","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1126\/science.aax5863","volume":"367","author":"HJ Uckelmann","year":"2020","unstructured":"Uckelmann HJ, Kim SM, Wong EM, Hatton C, Giovinazzo H, Gadrey JY, et al. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science. 2020;367:586\u201390.","journal-title":"Science"},{"key":"3014_CR38","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","volume":"615","author":"F Perner","year":"2023","unstructured":"Perner F, Stein EM, Wenge DV, Singh S, Kim J, Apazidis A, et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature. 2023;615:913\u20139.","journal-title":"Nature"},{"key":"3014_CR39","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1182\/blood.2023022480","volume":"144","author":"MC Kwon","year":"2024","unstructured":"Kwon MC, Thuring JW, Querolle O, Dai X, Verhulst T, Pande V, et al. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. Blood. 2024;144:1206\u201320.","journal-title":"Blood"},{"key":"3014_CR40","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41551-020-00625-5","volume":"5","author":"G Xie","year":"2021","unstructured":"Xie G, Ivica NA, Jia B, Li Y, Dong H, Liang Y, et al. CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia. Nat Biomed Eng. 2021;5:399\u2013413.","journal-title":"Nat Biomed Eng"},{"key":"3014_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200797","volume":"32","author":"K Teppert","year":"2024","unstructured":"Teppert K, Yonezawa Ogusuku IE, Brandes C, Herbel V, Winter N, Werchau N, et al. CAR\u2019TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment. Mol Ther Oncol. 2024;32:200797.","journal-title":"Mol Ther Oncol"},{"key":"3014_CR42","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","volume":"23","author":"Q Tang","year":"2024","unstructured":"Tang Q, Khvorova A. RNAi-based drug design: considerations and future directions. Nat Rev Drug Discov. 2024;23:341\u201364.","journal-title":"Nat Rev Drug Discov"},{"key":"3014_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature04688","volume":"441","author":"TS Zimmermann","year":"2006","unstructured":"Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441:111\u20134.","journal-title":"Nature"},{"key":"3014_CR44","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5:101.","journal-title":"Signal Transduct Target Ther"},{"key":"3014_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11\u201321.","journal-title":"N Engl J Med"},{"key":"3014_CR46","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ymthe.2024.01.005","volume":"32","author":"M Moazzam","year":"2024","unstructured":"Moazzam M, Zhang M, Hussain A, Yu X, Huang J, Huang Y. The landscape of nanoparticle-based siRNA delivery and therapeutic development. Mol Ther. 2024;32:284\u2013312.","journal-title":"Mol Ther"},{"key":"3014_CR47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/jcph.1480","volume":"60","author":"X Zhang","year":"2020","unstructured":"Zhang X, Goel V, Attarwala H, Sweetser MT, Clausen VA, Robbie GJ. Patisiran pharmacokinetics, pharmacodynamics, and exposure-response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. J Clin Pharm. 2020;60:37\u201349.","journal-title":"J Clin Pharm"},{"key":"3014_CR48","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41375-023-01854-8","volume":"37","author":"H Issa","year":"2023","unstructured":"Issa H, Swart LE, Rasouli M, Ashtiani M, Nakjang S, Jyotsana N, et al. Nanoparticle-mediated targeting of the fusion gene RUNX1\/ETO in t(8;21)-positive acute myeloid leukaemia. Leukemia. 2023;37:820\u201334.","journal-title":"Leukemia"},{"key":"3014_CR49","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/leu.2017.269","volume":"32","author":"N Jyotsana","year":"2018","unstructured":"Jyotsana N, Sharma A, Chaturvedi A, Scherr M, Kuchenbauer F, Sajti L, et al. RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo. Leukemia. 2018;32:224\u20136.","journal-title":"Leukemia"},{"key":"3014_CR50","doi-asserted-by":"publisher","first-page":"E16","DOI":"10.1073\/pnas.1519273113","volume":"113","author":"S Weinstein","year":"2016","unstructured":"Weinstein S, Toker IA, Emmanuel R, Ramishetti S, Hazan-Halevy I, Rosenblum D, et al. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. Proc Natl Acad Sci USA. 2016;113:E16\u201322.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3014_CR51","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jconrel.2010.02.020","volume":"144","author":"M Rothdiener","year":"2010","unstructured":"Rothdiener M, M\u00fcller D, Castro PG, Scholz A, Schwemmlein M, Fey G, et al. Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems. J Control Release. 2010;144:251\u20138.","journal-title":"J Control Release"},{"key":"3014_CR52","doi-asserted-by":"crossref","unstructured":"Mohanty S, Jyotsana N, Sharma A, Kloos A, Gabdoulline R, Othman B, et al. Targeted inhibition of the NUP98-NSD1 fusion oncogene in acute myeloid leukemia. Cancers. 2020;12:2766.","DOI":"10.3390\/cancers12102766"},{"key":"3014_CR53","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13045-022-01390-5","volume":"15","author":"N B\u00e4umer","year":"2022","unstructured":"B\u00e4umer N, Scheller A, Wittmann L, Faust A, Apel M, Nimmagadda SC, et al. Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia. J Hematol Oncol. 2022;15:171.","journal-title":"J Hematol Oncol"},{"key":"3014_CR54","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jconrel.2024.02.018","volume":"367","author":"ASKCR Ansari","year":"2024","unstructured":"Ansari ASKCR, Morales LC, Nasrullah M, Meenakshi Sundaram DN, Kucharski C, et al. Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models. J Control Rel. 2024;367:821\u201336.","journal-title":"J Control Rel"},{"key":"3014_CR55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jconrel.2019.08.018","volume":"310","author":"J Valencia-Serna","year":"2019","unstructured":"Valencia-Serna J, Kucharski C, Chen M, Kc R, Jiang X, Brandwein J, et al. siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers. J Control Rel. 2019;310:141\u201354.","journal-title":"J Control Rel"},{"key":"3014_CR56","doi-asserted-by":"publisher","first-page":"e44197","DOI":"10.1371\/journal.pone.0044197","volume":"7","author":"B Landry","year":"2012","unstructured":"Landry B, Aliabadi HM, Samuel A, G\u00fcl-Uluda\u011f H, Jiang X, Kutsch O, et al. Effective non-viral delivery of siRNA to acute myeloid leukemia cells with lipid-substituted polyethylenimines. PLoS One. 2012;7:e44197.","journal-title":"PLoS One"},{"key":"3014_CR57","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1182\/blood-2005-05-2168","volume":"106","author":"RG Verhaak","year":"2005","unstructured":"Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106:3747\u201354.","journal-title":"Blood"},{"key":"3014_CR58","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","volume":"26","author":"DJ Foster","year":"2018","unstructured":"Foster DJ, Brown CR, Shaikh S, Trapp C, Schlegel MK, Qian K, et al. Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates. Mol Ther. 2018;26:708\u201317.","journal-title":"Mol Ther"},{"key":"3014_CR59","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13072-021-00432-5","volume":"14","author":"C Baumann","year":"2021","unstructured":"Baumann C, Zhang X, Zhu L, Fan Y, De La Fuente R. Changes in chromatin accessibility landscape and histone H3 core acetylation during valproic acid-induced differentiation of embryonic stem cells. Epigenet Chromatin. 2021;14:58.","journal-title":"Epigenet Chromatin"},{"key":"3014_CR60","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nature13714","volume":"516","author":"TJ Stasevich","year":"2014","unstructured":"Stasevich TJ, Hayashi-Takanaka Y, Sato Y, Maehara K, Ohkawa Y, Sakata-Sogawa K, et al. Regulation of RNA polymerase II activation by histone acetylation in single living cells. Nature. 2014;516:272\u20135.","journal-title":"Nature"},{"key":"3014_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2020.118879","volume":"1868","author":"M Okuwaki","year":"2021","unstructured":"Okuwaki M, Saito S, Hirawake-Mogi H, Nagata K. The interaction between nucleophosmin\/NPM1 and the large ribosomal subunit precursors contribute to maintaining the nucleolar structure. Biochim Biophys Acta Mol Cell Res. 2021;1868:118879.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"3014_CR62","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41557-024-01663-1","volume":"17","author":"K Li","year":"2025","unstructured":"Li K, Xie X, Gao R, Chen Z, Yang M, Wen Z, et al. Spatiotemporal protein interactome profiling through condensation-enhanced photocrosslinking. Nat Chem. 2025;17:111\u201323.","journal-title":"Nat Chem"},{"key":"3014_CR63","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41375-024-02438-w","volume":"39","author":"Y Shimosato","year":"2025","unstructured":"Shimosato Y, Yamamoto K, Jia Y, Zhang W, Shiba N, Hayashi Y, et al. NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation. Leukemia. 2025;39:75\u201386.","journal-title":"Leukemia"},{"key":"3014_CR64","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18:421\u201346.","journal-title":"Nat Rev Drug Discov"},{"key":"3014_CR65","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/2159-8290.CD-21-1307","volume":"12","author":"Y Liu","year":"2022","unstructured":"Liu Y, Li Q, Alikarami F, Barrett DR, Mahdavi L, Li H, et al. Small-molecule inhibition of the acyl-lysine reader ENL as a strategy against acute myeloid leukemia. Cancer Discov. 2022;12:2684\u2013709.","journal-title":"Cancer Discov"},{"key":"3014_CR66","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1182\/blood.2019003538","volume":"135","author":"J Long","year":"2020","unstructured":"Long J, Jia MY, Fang WY, Chen XJ, Mu LL, Wang ZY, et al. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia. Blood. 2020;135:1472\u201383.","journal-title":"Blood"},{"key":"3014_CR67","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","volume":"35","author":"GC Issa","year":"2021","unstructured":"Issa GC, Ravandi F, DiNardo CD, Jabbour E, Kantarjian HM, Andreeff M. Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021;35:2482\u201395.","journal-title":"Leukemia"},{"key":"3014_CR68","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","volume":"123","author":"A Yokoyama","year":"2005","unstructured":"Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell. 2005;123:207\u201318.","journal-title":"Cell"},{"key":"3014_CR69","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-024-01632-8","volume":"17","author":"KVG Nadiminti","year":"2024","unstructured":"Nadiminti KVG, Sahasrabudhe KD, Liu H. Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead. J Hematol Oncol. 2024;17:113.","journal-title":"J Hematol Oncol"},{"key":"3014_CR70","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1182\/blood-2005-04-1733","volume":"106","author":"T Suzuki","year":"2005","unstructured":"Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood. 2005;106:2854\u201361.","journal-title":"Blood"},{"key":"3014_CR71","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1182\/blood-2005-05-2164","volume":"106","author":"K D\u00f6hner","year":"2005","unstructured":"D\u00f6hner K, Schlenk RF, Habdank M, Scholl C, R\u00fccker FG, Corbacioglu A, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106:3740\u20136.","journal-title":"Blood"},{"key":"3014_CR72","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood-2005-06-2248","volume":"106","author":"S Schnittger","year":"2005","unstructured":"Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106:3733\u20139.","journal-title":"Blood"},{"key":"3014_CR73","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1182\/blood-2005-08-3167","volume":"107","author":"C Thiede","year":"2006","unstructured":"Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107:4011\u201320.","journal-title":"Blood"},{"key":"3014_CR74","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41586-019-1835-6","volume":"577","author":"L MacPherson","year":"2020","unstructured":"MacPherson L, Anokye J, Yeung MM, Lam EYN, Chan YC, Weng CF, et al. HBO1 is required for the maintenance of leukaemia stem cells. Nature. 2020;577:266\u201370.","journal-title":"Nature"},{"key":"3014_CR75","doi-asserted-by":"crossref","unstructured":"Michmerhuizen NL, Heikamp EB, Iacobucci I, Umeda M, Arthur B, Mishra V, et al. KAT6A and KAT7 Histone Acetyltransferase Complexes Are Molecular Dependencies and Therapeutic Targets in NUP98-Rearranged Acute Myeloid Leukemia. Cancer Discov. 2025;15:2096\u2013116 .","DOI":"10.1158\/2159-8290.CD-24-1772"},{"key":"3014_CR76","doi-asserted-by":"crossref","unstructured":"Gordon SJV, Perner F, MacPherson L, Fennell KA, Wenge DV, Bourgeois W, et al. Catalytic inhibition of KAT6\/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia. Cancer Discov. 2025;15:2117\u201338.","DOI":"10.1158\/2159-8290.CD-24-1517"},{"key":"3014_CR77","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41375-020-1001-z","volume":"35","author":"YZ Au","year":"2021","unstructured":"Au YZ, Gu M, De Braekeleer E, Gozdecka M, Aspris D, Tarumoto Y, et al. KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements. Leukemia. 2021;35:1012\u201322.","journal-title":"Leukemia"},{"key":"3014_CR78","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.ccell.2023.11.001","volume":"41","author":"L Nicosia","year":"2023","unstructured":"Nicosia L, Spencer GJ, Brooks N, Amaral FMR, Basma NJ, Chadwick JA, et al. Therapeutic targeting of EP300\/CBP by bromodomain inhibition in hematologic malignancies. Cancer Cell. 2023;41:2136\u2013.e2113.","journal-title":"Cancer Cell"},{"key":"3014_CR79","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1182\/blood.2022019306","volume":"145","author":"V Shah","year":"2025","unstructured":"Shah V, Giotopoulos G, Osaki H, Meyerh\u00f6fer M, Meduri E, Gallego-Crespo A, et al. Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation. Blood. 2025;145:748\u201364.","journal-title":"Blood"},{"key":"3014_CR80","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1038\/leu.2013.77","volume":"27","author":"A Mupo","year":"2013","unstructured":"Mupo A, Celani L, Dovey O, Cooper JL, Grove C, Rad R, et al. A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. Leukemia. 2013;27:1917\u201320.","journal-title":"Leukemia"},{"key":"3014_CR81","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1038\/leu.2013.114","volume":"27","author":"M Mallardo","year":"2013","unstructured":"Mallardo M, Caronno A, Pruneri G, Raviele PR, Viale A, Pelicci PG, et al. NPMc+ and FLT3_ITD mutations cooperate in inducing acute leukaemia in a novel mouse model. Leukemia. 2013;27:2248\u201351.","journal-title":"Leukemia"},{"key":"3014_CR82","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/s41375-018-0368-6","volume":"33","author":"MA Loberg","year":"2019","unstructured":"Loberg MA, Bell RK, Goodwin LO, Eudy E, Miles LA, SanMiguel JM, et al. Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis. Leukemia. 2019;33:1635\u201349.","journal-title":"Leukemia"},{"key":"3014_CR83","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1182\/blood.2018883140","volume":"134","author":"A Rudorf","year":"2019","unstructured":"Rudorf A, M\u00fcller TA, Klingeberg C, Kreutmair S, Poggio T, Gorantla SP, et al. NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia. Blood. 2019;134:383\u20138.","journal-title":"Blood"},{"key":"3014_CR84","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1182\/blood-2017-01-760595","volume":"130","author":"OM Dovey","year":"2017","unstructured":"Dovey OM, Cooper JL, Mupo A, Grove CS, Lynn C, Conte N, et al. Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia. Blood. 2017;130:1911\u201322.","journal-title":"Blood"},{"key":"3014_CR85","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1182\/blood.2019003339","volume":"135","author":"MF Bezerra","year":"2020","unstructured":"Bezerra MF, Lima AS, Piqu\u00e9-Borr\u00e0s MR, Silveira DR, Coelho-Silva JL, Pereira-Martins DA, et al. Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. Blood. 2020;135:870\u20135.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03014-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03014-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03014-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:08:07Z","timestamp":1785521287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03014-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":85,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3014"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03014-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Xiamen University has filed a provisional patent application in connection with this work.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors confirm that all methods were performed in accordance with the relevant guidelines and regulations. All human samples were collected with written informed consent in accordance with the Declaration of Helsinki and approval by the Institutional Ethics Committee of Tongji Hospital (Shanghai, China, Approval No. SBKT-2021-103). All animal experiments were approved by the Laboratory Animal Care and Use Committee of Xiamen University, and were conducted in strict accordance with the good veterinary practices defined by the Laboratory Animal Center of Xiamen University (Approval No. XMULAC20200225 and XMULAC20210194).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}